Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 20/20 | 1.00 |
| ▸ | ACVRL1 | P37023 | 19/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 16/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 13/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 17/20 | 0.88 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.61 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.61 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.61 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.61 |
| ▸ | BMP4 | P12644 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135065 | 1.00 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL16134982 | 0.94 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL24409667 | 0.94 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL17531625 | 0.90 | ACVRL1 (0.82) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL19627063 | 0.90 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL16111725 | 0.85 | ACVRL1 (0.74) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL17531623 | 0.83 | ACVR1B (0.81) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL24409711 | 0.83 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL16112502 | 0.83 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B | |
| SCHEMBL16112127 | 0.82 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1AACVR1BBMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081212-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022098812-A1 | METHODS OF TREATING IRON OVERLOAD | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098821-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099166-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |